Article Sidebar

Submitted
Nov 4, 2024
Published
Nov 4, 2024
Download
PDF
Statistic
Read Counter : 25 Download : 15

Main Article Content

Abstract

Diabetes mellitus is a most common endocrine disorder, affecting more than 300 million people worldwide. For these therapies developed along the principles of allopathic are often limited in efficacy, Carry the risk of adverse effects, and are often too costly, especially for the developing world. In order to identify complementary or alternative approaches to existing medications, we studied the anti-diabetic potential of leaves of Alovera. The acute oral toxicity studies of the extracts revealed no toxic effects up to the levels of 2000mg/kg b.wt. The aqueous and alcoholic extracts of 20 and 30mg/kg body weight of Aloverawas screened for the presence of hypoglycemic and antidiabetic activity. In this study diabetes was induced by a single IP dose Alloxan monohydrate in 72hrs fasted rats. The FBGL was carried on 7th, 14th and 21st day and OGTT was measured on 8th, 15th and 22nd day. Glibeclamide was taken as the standard and the results are quite comparable with it. The studies were indicated that the leaves of Aloveraare effective in regeneration of insulin secreting β-cells and thus possess antidiabetic activity. The aqueous and alcoholic extracts showed significant effect in decreasing the Fasting blood Glucose level and oral glucose tolerance test of rats and it’s also showed good hypoglycemic activity in normal glycemic rats. The preliminary phytochemical analysis of the extracts of Aloverarevealed the presence of Alkaloids, Tannins, Anthraquinones, Flavonoids, Saponins, Triterpenes, Sterols, Coumarinas the possible biologically active principles.

Keywords

Alovera Alloxan monohydrate Glibenclamide FBGL and OGTT

Article Details

How to Cite
Chowhan Anjali, B. Sandeep, & L. Harikiran. (2024). Pharmacological Screening And Phytochemical Evaluation Of Anti-Diabetic Activity Of Alovera In Alloxan Induced Diabetic Rats. International Journal of Research in Pharmacology & Pharmacotherapeutics, 13(4), 454-465. Retrieved from https://ijrpp.com/ijrpp/article/view/577
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. 1. Consultation, W. H. O. Definition, diagnosis and classification of diabetes mellitus and its complications. Vol. 1. Part, 1999.
  2. 2. Alberti, Kurt George Matthew Mayer, and PZ ft Zimmet. "Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation." Diabetic medicine 15.7 (1998): 539-553.
  3. 3. Gress, Todd W., et al. "Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus." New England Journal of Medicine 342.13 (2000): 905-912.
  4. 4. Ahmed, Awad M. "History of diabetes mellitus." Saudi medical journal 23.4 (2002): 373-378.
  5. 5. Zimmet, Paul Z., Daniel J. McCarty, and Maximilian P. de Courten. "The global epidemiology of non-insulin-dependent diabetes mellitus and the metabolic syndrome." Journal of Diabetes and its Complications 11.2 (1997): 60-68.
  6. 6. American Diabetes Association. "Type 2 diabetes in children and adolescents."Pediatrics 105.3 (2000): 671-680.
  7. 7. Saltiel, Alan R., and C. Ronald Kahn. "Insulin signalling and the regulation of glucose and lipid metabolism." Nature 414.6865 (2001): 799-806.
  8. 8. Browning, Jeffrey D., and Jay D. Horton. "Molecular mediators of hepatic steatosis and liver injury." Journal of Clinical Investigation 114.2 (2004): 147-152.
  9. 9. Aronoff, Stephen L., et al. "Glucose metabolism and regulation: beyond insulin and glucagon." Diabetes Spectrum 17.3 (2004): 183-190.
  10. 10. Ross, E. J., and D. C. Linch. "Cushing's syndrome—killing disease: discriminatory value of signs and symptoms aiding early diagnosis." The Lancet320.8299 (1982): 646-649.
  11. 11. Levin, Marvin E., Vincenza C. Boisseau, and Louis V. Avioli. "Effects of diabetes mellitus on bone mass in juvenile and adult-onset diabetes." New England Journal of Medicine 294.5 (1976): 241-245.
  12. 12. Sherwin, Robert, and Philip Felig. "Pathophysiology of diabetes mellitus." The Medical clinics of North America 62.4 (1978): 695-711.
  13. 13. Faber, O. K., and C. Binder. "C-peptide response to glucagon: a test for the residual β-cell function in diabetes mellitus." Diabetes 26.7 (1977): 605-610.
  14. 14. Ioannidis, Ioannis. "Pathophysiology of Type 1 diabetes." Diabetes in Clinical Practice: Questions and Answers from Case Studies 31 (2007): 23.
  15. 15. Scheen, A. J. "Pathophysiology of type 2 diabetes." Acta Clinica Belgica 58.6 (2003): 335-341.